Literature DB >> 21320116

Relationship of clinical and quality of life trajectories following the onset of seizures: findings from the UK MESS Study.

Ann Jacoby1, Steven Lane, Anthony Marson, Gus A Baker.   

Abstract

PURPOSE: We defined a series of clinical trajectories represented among adult patients with new-onset seizures across a 4-year follow-up period; and linked these clinical trajectories to the quality of life (QOL) profiles and trajectories of those experiencing them. We examined both between- and within-group differences.
METHODS: Analyses were based on 253 individuals completing QOL questionnaires at baseline and 2 and 4 years subsequently. Based on patient self-report, we defined five "clinical trajectory" groups: individuals experiencing a single seizure only; individuals entering early remission; individuals experiencing late remission; individuals initially becoming seizure-free but subsequently relapsing; individuals with seizures persisting throughout follow-up. QOL profiles at each time point were compared using a validated QOL battery, NEWQOL. KEY
FINDINGS: Even at baseline, there were significant between-group differences, with patients experiencing a single seizure only reporting the best QOL profile and those with seizures subsequently persisting across all time points reporting the worst. By 2 years, the QOL profiles of individuals experiencing early remission were similar to those of single seizure patients, as were those for late remission and relapse patients. SIGNIFICANCE: A consistent pattern was seen, with "single seizure" individuals doing best and individuals with persistent seizures doing worst. Of particular concern is that even at baseline, individuals whose seizures persisted were doing poorly for QOL, suggesting the possibility that underlying neurobiologic mechanisms were operating. In contrast, our findings support previous reports of only short-lived and small QOL decrements for individuals experiencing a single or few seizures. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21320116     DOI: 10.1111/j.1528-1167.2010.02973.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  7 in total

1.  [Impact of early benefit assessment on patients with epilepsy in Germany: Current healthcare provision and therapeutic needs].

Authors:  A Strzelczyk; H M Hamer
Journal:  Nervenarzt       Date:  2016-04       Impact factor: 1.214

Review 2.  Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan.

Authors:  Jack J Lin; Marco Mula; Bruce P Hermann
Journal:  Lancet       Date:  2012-09-29       Impact factor: 79.321

3.  Formularies, costs, and quality of care: Limiting formularies is not harmful to patients.

Authors:  William N Jones
Journal:  Neurol Clin Pract       Date:  2013-02

Review 4.  The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experience.

Authors:  Sebastian Bauer; Laurent M Willems; Esther Paule; Christine Petschow; Johann Philipp Zöllner; Felix Rosenow; Adam Strzelczyk
Journal:  Ther Adv Neurol Disord       Date:  2016-11-29       Impact factor: 6.570

5.  Seizures and epilepsy in multiple sclerosis: epidemiology and prognosis in a large tertiary referral center.

Authors:  Lisa Langenbruch; Julia Krämer; Sati Güler; Gabriel Möddel; Sophia Geßner; Nico Melzer; Christian E Elger; Heinz Wiendl; Thomas Budde; Sven G Meuth; Stjepana Kovac
Journal:  J Neurol       Date:  2019-05-08       Impact factor: 4.849

6.  A genome-wide association study and biological pathway analysis of epilepsy prognosis in a prospective cohort of newly treated epilepsy.

Authors:  Doug Speed; Clive Hoggart; Slave Petrovski; Ioanna Tachmazidou; Alison Coffey; Andrea Jorgensen; Hariklia Eleftherohorinou; Maria De Iorio; Marian Todaro; Tisham De; David Smith; Philip E Smith; Margaret Jackson; Paul Cooper; Mark Kellett; Stephen Howell; Mark Newton; Raju Yerra; Meng Tan; Chris French; Markus Reuber; Graeme E Sills; David Chadwick; Munir Pirmohamed; David Bentley; Ingrid Scheffer; Samuel Berkovic; David Balding; Aarno Palotie; Anthony Marson; Terence J O'Brien; Michael R Johnson
Journal:  Hum Mol Genet       Date:  2013-08-19       Impact factor: 6.150

7.  Investigating imaging network markers of cognitive dysfunction and pharmacoresistance in newly diagnosed epilepsy: a protocol for an observational cohort study in the UK.

Authors:  Christophe de Bézenac; Marta Garcia-Finana; Gus Baker; Perry Moore; Nicola Leek; Rajiv Mohanraj; Leonardo Bonilha; Mark Richardson; Anthony Guy Marson; Simon Keller
Journal:  BMJ Open       Date:  2019-10-16       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.